Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis

Inclusion Criteria:

1. Expanded Disability Status Scale mark 1.5 - 4.5
2. Fatigue Severity Scale > 4
3. Beck Depression Inventory < 30
4. No relapse for, at least, three month prior to screening
5. Drug washout period = 4 weeks for any fatigue aimed drug
6. Patient capable to sign the informed consent

Exclusion Criteria:

1. Fatigue causing disease other than multiple sclerosis:
2. sleep apnea
3. other autoimmune disease that could be explain the fatigue.
4. endocrine autoimmune disease if the blood test is not in range in the last 6month.
5. patient with diagnosis of chronic fatigue
6. Patient with high blood pressure out of range or decompensated heart failure orNew York Heart Association (NYHA) 3-4.
7. Secondary Epilepsy or neuropathic chronic pain which requires continuous treatment.
8. Contraindication for trial treatment:
9. Some kind of magnetic metal.
10. Epilepsy antecedents.
11. Any drugs that could decrease the seizure threshold
12. Amantadine sensitivity
13. Cardiopathy disease, severe kidney failure, Angle-closure glaucoma
14. Breastfeeding, pregnancy, or pregnancy planning phase in the next year. Ofchildbearing potential and willing to use an acceptable method of contraception duringthe study period.
15. Patient with a terminal disease with no more than one year life expectancy.
16. Patient has been treated for a maligned disease in the past three years.
17. A scheduled surgery in the course of the trials.
18. Any condition that a member of research team consider could affect toparticipation/follow up patient.
19. Alcoholic o toxics condition in the last year.
20. Major mental disorders
21. Poor communication skills or poor cognitive condition.
22. Other trial participation in the previous 4 month.
23. Use a chronic drug that could interfere in the clinical outcome.